Ligand, SelectRA Pharmaceuticals Inc. news

LGNDA President and CEO David Robinson told BioCentury that "to discover sub-type receptor selective compounds, you have to test them against a panel of receptors, We believe they have deployed the assay, the RAR gene and the RAR receptor element for some of their work."

LGNDA is also suing SRI for breach of a contract between SRI and LGNDA giving the latter the first right to evaluate retinoid compounds synthesized at SRI. ...